Surgery Partners(SGRY) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company reported full year net revenue of $3.3 billion, up 6.2% year-over-year, with same facility revenue growth of 4.9% [4][25] - Full year Adjusted EBITDA was $526 million, up 3.5% year-over-year, but significantly below expectations, with an Adjusted EBITDA margin of 15.9%, reflecting 40 basis points of margin compression [4][26] - Fourth quarter revenue grew 2.4% to $885 million, with Adjusted EBITDA of $156.9 million and a margin of 17.7% [24][25] Business Line Data and Key Metrics Changes - The company performed nearly 670,000 surgical cases in 2025, a 2% increase from 2024, with same facility case growth of 1.3% in the fourth quarter [7][24] - Orthopedic cases grew significantly, with total joint replacements increasing by 15% in the fourth quarter and 19% year-to-date compared to the previous year [8] - Physician recruitment remained strong with almost 700 physicians recruited in 2025, although some transitions affected payer mix [9] Market Data and Key Metrics Changes - The company experienced a decline in commercial payer mix, particularly in three surgical hospital markets, which faced slower case growth and shifts in payer dynamics [5][10] - The fourth quarter saw a significant pressure on payer mix, with a 370 basis point decline in commercial patients compared to the previous year [79] Company Strategy and Development Direction - The company remains committed to its growth algorithm, focusing on organic, de novo, and acquired growth, while optimizing its portfolio to enhance shareholder value [6][12] - M&A is a critical component of the growth strategy, with a disciplined approach to capital allocation and a strong pipeline of opportunities [13][35] - The company is executing a comprehensive portfolio optimization strategy aimed at improving balance sheet strength without sacrificing growth [15][36] Management's Comments on Operating Environment and Future Outlook - Management acknowledged significant headwinds in the second half of the year, particularly in surgical hospitals, but expressed confidence in long-term growth opportunities [5][6] - The initial guidance for 2026 is net revenue of $3.35 billion to $3.45 billion, with Adjusted EBITDA of at least $530 million, reflecting anticipated headwinds [18][33] - Management emphasized the importance of addressing near-term challenges while remaining optimistic about structural tailwinds in the ASC market [20][36] Other Important Information - The board authorized a share repurchase program of up to $200 million, reflecting confidence in the company's future and capital allocation strategy [22][84] - The company appointed Lloyd Dean as a new director, bringing valuable healthcare experience to support growth [22] Q&A Session Summary Question: Challenges of headwinds and volume dynamics - Management acknowledged the challenges but emphasized the value created in the healthcare space and the belief in growth opportunities despite current pressures [40][41] Question: Recovery of surgical hospital markets - Management indicated that while there are pressures, they do not expect a repeat of the current issues and are focused on turnaround plans [70] Question: Breakdown of same-store revenue guidance - The breakdown between price and volume in the 3% same-store revenue guidance is roughly even [60] Question: Capital deployment and share buyback - Management stated that capital deployment will be measured against all potential uses, including share buybacks, while focusing on deleveraging [53][82]